3,7,8,2'-Tetrahydroxyflavone
3,7-Dihydroxyflavone
4'-Dimethylamino-7,8-dihydroxyflavone
7,3′-Dihydroxyflavone
7,8,2'-Trihydroxyflavone
7,8,3'-Trihydroxyflavone
7,8-Dihydroxyflavone
ABT-110
ALE-0540
AM7 (drug)
AMG-458
ANA-12
ANXA2
ASP-6294
ATC code L01
AVE-1642
AZD-6918
Abagovomab
Abemaciclib
Abituzumab
Acalabrutinib
Adagrasib
Adecatumumab
Adipotide
Adrenomedullin
Afatinib
Aflibercept
Agerafenib
Alacizumab pegol
Alectinib
Alemtuzumab
Alpelisib
Altiratinib
Amatuximab
American Society of Health-System Pharmacists
Amitriptyline
Amivantamab (data page)
Amphiregulin
Amuvatinib
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Ancestim
Angiopoietin 1
Angiopoietin 2
Angiopoietin 3
Angiopoietin 4
Angiopoietin receptor
Antigen
Antineoplastic
Aprutumab
Aprutumab ixadotin
Artemin
Asciminib
Ascrinvacumab
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
Axokine
BMS-754807
BMS-777607
BNN-20
BNN-27
BRAF (gene)
Balstilimab
Baricitinib
Bavituximab
Bcr-abl fusion protein
Becaplermin
Bectumomab
Belantamab mafodotin
Bermekimab
Betacellulin
Bevacizumab
Binimetinib
Bispecific monoclonal antibody
Bivatuzumab mertansine
Blinatumomab
Bosutinib
Botensilimab
Brain-derived neurotrophic factor
Brentuximab vedotin
Brigatinib
Brontictuzumab
Bruton's tyrosine kinase
Burosumab
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CE-245677
CH-7057288
CSPG5
Cabozantinib
Cancer immunotherapy
Canertinib
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carboplatin
Carotuximab
Catumaxomab
Cediranib
Cemiplimab
Cenegermin
Cerebrolysin
Ceritinib
Cetuximab
Chemical formula
Chimeric antibody
Ciliary neurotrophic factor receptor
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Colony-stimulating factor
Committee for Medicinal Products for Human Use
Conatumumab
Connective tissue growth factor
Copanlisib
Copyright status of works by the federal government of the United States
Cosibelimab
Crenolanib
Crizotinib
Cyclotraxin B
DMAQ-B1
DS-6051
Dabrafenib
Dacetuzumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Dapiclermin
Daratumumab
Dasatinib
Dehydroepiandrosterone
Dehydroepiandrosterone sulfate
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Deoxygedunin
Depatuxizumab
Depatuxizumab mafodotin
Deprenyl
Des(1-3)IGF-1
Detumomab
Dexamethasone
Dihexa
Dinutuximab
Dinutuximab beta
Diosmetin
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug class
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EFNA1
EFNA2
EFNA3
EFNA4
EFNA5
EFNB1
EFNB2
EFNB3
EML4
EVT-901
Ecromeximab
Edrecolomab
Elotuzumab
Elranatamab
Emactuzumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Ephrin
Epidermal growth factor
Epidermal growth factor receptor
Epigen
Epiregulin
ErbB
Erdafitinib
Erlotinib
Ersofermin
Ertumaxomab
Erythropoietin
Etaracizumab
European Medicines Agency
Everolimus
Evinacumab
Exotoxin
FGF1
FGF10
FGF15/19
FGF17
FGF18
FGF19
FGF2
FGF20
FGF22
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FX007
Farletuzumab
Fasinumab
Fedratinib
Fibroblast growth factor
Fibroblast growth factor receptor
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Ficlatuzumab
Figitumumab
Filgotinib
First-in-class medication
Flanvotumab
Flotetuzumab
Food and Drug Administration
Foretinib
Fosgonimeton
Frunevetmab
Fruquintinib
Fulranumab
Fusion protein
Futibatinib
Futuximab
GBR-900
GFRα1
GFRα2
GFRα3
GFRα4
GZ-389988
Gambogic amide
Ganitumab
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glia maturation factor
Glial cell line-derived neurotrophic factor
Glofitamab
Glucose-6-phosphate isomerase
Glypromate
Golvatinib
Gossypetin
Grandinin
Growth factor receptor
HER2/neu
HER3
HER4
HIOC
Hdl (identifier)
Hedgehog signaling pathway
Heparin-binding EGF-like growth factor
Hepatocyte growth factor
Hepatocyte growth factor receptor
Hepatoma-derived growth factor
Human
Humanized antibody
IGF-1 LR3
IGFBP1
IGFBP2
IGFBP3
IGFBP4
IGFBP5
IGFBP6
IGFBP7
INCB28060
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Inavolisib
Indatuximab ravtansine
Indication (medicine)
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Infigratinib
Inotuzumab ozogamicin
Insulin
Insulin-like growth factor-binding protein
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor 2
Insulin-like growth factor 2 receptor
Interleukin
Interleukin 2
International nonproprietary name
Intetumumab
Intravenous therapy
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Istiratumab
JNJ-38877605
Janus kinase
K252a
KEGG
KRAS
Keratinocyte growth factor
LEVI-04
LM22A-4
Labetuzumab
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Leukemia inhibitory factor
Lexatumumab
Liatermin
Lifastuzumab vedotin
Lilotomab
Linsitinib
Lintuzumab
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Low-affinity nerve growth factor receptor
Lucatumumab
Lumretuzumab
Lymphatic system
Lymphoma
MEDI-578
MEN1
MK-2461
MTOR inhibitor
Macrophage-stimulating protein
Mapatumumab
Margetuximab
Masitinib
Matuzumab
Mecasermin
Mecasermin rinfabate
MedlinePlus
Mesenchymal–epithelial transition
Midkine
Midostaurin
Migration-stimulating factor
Milatuzumab
Milciclib
Minretumomab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Mosunetuzumab
Motesanib
Moxetumomab pasudotox
Mubritinib
Murodermin
Myeloid
N-Acetylserotonin
NRG2
NRG3
NRG4
NVP-ADW742
NVP-AEW541
Nacolomab tafenatox
Naptumomab estafenatox
Narnatumab
Naxitamab
Necitumumab
Neoplasm
Nepidermin
Neratinib
Nerve growth factor
Nesvacumab
Neuregulin
Neuregulin-1
Neurotrophin-3
Neurotrophin-4
Neurturin
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small-cell lung cancer
Non-small cell lung cancer
Norwogonin
ONO-4474
ONO-5390556
OSl-906
Obinutuzumab
Ocaratuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Onartuzumab
Oncomodulin
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otlertuzumab
PDGFA
PDGFB
PDGFC
PDGFD
PF-04217903
PF-2341066
PHA-665752
PLX-7486
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Palifermin
Panitumumab
Parsaclisib
Parsatuzumab
Patritumab
Pazopanib
Pegaptanib
Pembrolizumab
Pemetrexed
Pemigatinib
Pemtumomab
Persephin
Pertuzumab
Pexidartinib
Phases of clinical research
Pi3K inhibitor
Pinatuzumab vedotin
Pirtobrutinib
Pituitary adenylate cyclase-activating peptide
Placental growth factor
Platelet-derived growth factor
Platelet-derived growth factor receptor
Pleiotrophin
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Protein Data Bank
Public domain
Puce
Quizartinib
R13 (drug)
R1507
R7 (drug)
RBM-004
RET proto-oncogene
RTK class III